PMID: 9185704Jun 11, 1997Paper

Targeting BCL1 lymphoma with anti-idiotype antibodies: biodistribution kinetics of directly labeled antibodies and bispecific antibody-targeted bivalent haptens

International Journal of Cancer. Journal International Du Cancer
C ManettiJ M Le Doussal

Abstract

The mouse BCL1 lymphoma model has been used for evaluating immunotherapy with anti-idiotype (anti-Id) antibodies, including Id immunisation, IgG therapy and bispecific (Bs) antibody-targeted cytotoxicity. Here, we provide quantitative data on the targeting of small (25 +/- 12 mg) intrasplenic BCL1 tumours, using anti-Id IgG, F(ab')2 and anti-Id x anti-hapten BsF(ab')2 covalently labelled with 125iodine, as well as noncovalent complexes of BsF(ab')2 and 125I-labelled bivalent hapten. The results are the following: 1) up to 115% of the injected dose per gram (% ID/g) of spleen can be localised in the first hour, corresponding to approximately 600% ID/g of tumour; 2) localisation is specific for cell-surface Id; 3) optimal doses can overcome circulating Id; 4) circulating Id markedly increases the catabolism of IgG, thus impairing tumour localisation; 5) bivalent reagents are internalised by the target cells; 6) iodine covalently bound to bivalent antibodies [IgG, F(ab')2] is rapidly (T(1/2): 6-9 hr) released from the tumour; in contrast, the bivalent hapten is retained for a longer time (T(1/2): 25 hr); and 7) in the absence of bivalent hapten, the monovalent BsF(ab')2 is not rapidly internalised and dissociates from tumour cell-...Continue Reading

References

Apr 13, 1978·Nature·S Slavin, S Strober
Oct 1, 1990·Molecular Immunology·A MorelM Delaage
Oct 9, 1995·International Journal of Cancer. Journal International Du Cancer·C ManettiJ Barbet
Aug 12, 1993·The New England Journal of Medicine·M S KaminskiG M Butchko
Oct 21, 1993·The New England Journal of Medicine·O W PressB Porter
Jan 1, 1995·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·C P StannersA Fuks
Mar 1, 1993·Medical Physics·D J BuchsbaumB W Wessels
Jul 1, 1965·The Journal of Experimental Medicine·J L FAHEY, S SELL

❮ Previous
Next ❯

Citations

Jun 13, 2000·Cancer Biotherapy & Radiopharmaceuticals·J BarbetJ F Chatal
Apr 25, 2008·Current Protocols in Immunology·Arya Biragyn, Larry W Kwak
Jul 18, 2000·Bioconjugate Chemistry·M Hillairet de BoisferonA Gruaz-Guyon

❮ Previous
Next ❯

Related Concepts

Related Feeds

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.

Antibody Engineering

Antibody engineering technologies are constantly advancing to improve the clinical effectiveness of monoclonal and bispecific antibodies. Discover the latest research on Antibody Engineering here.